CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) shares traded down 1% on Monday. The company traded as low as $0.8551 and last traded at $0.9098. 47,321 shares traded hands during trading, an increase of 160% from the average daily volume of 18,234 shares. The stock had previously closed at $0.9188.
Wall Street Analysts Forecast Growth
GDTC has been the topic of a number of recent research reports. Fundamental Research set a $4.16 price target on shares of CytoMed Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of CytoMed Therapeutics in a report on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $4.16.
Read Our Latest Analysis on GDTC
CytoMed Therapeutics Trading Down 2.3%
The firm has a fifty day moving average price of $0.90 and a 200-day moving average price of $0.98.
CytoMed Therapeutics (NASDAQ:GDTC – Get Free Report) last posted its quarterly earnings results on Wednesday, September 30th. The company reported $0.05 EPS for the quarter. The company had revenue of $0.06 million during the quarter.
About CytoMed Therapeutics
CytoMed Therapeutics Limited (NASDAQ: GDTC) is a Singapore-based clinical-stage biopharmaceutical company focused on developing cell-based immunotherapies for the treatment of cancer. The company’s research centers on using immune cells to recognize and attack tumor cells, with an emphasis on developing therapies that may be produced from healthy donor cells for broader clinical use.
CytoMed is developing a pipeline of allogeneic cellular therapy candidates, including programs based on genetically modified T cells, natural killer T cells and gamma delta T cells.
Further Reading
- Five stocks we like better than CytoMed Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
